BiotechTube

PF-06730512

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Focal Segmental Glomerulosclerosis (FSGS)

Conditions

Focal Segmental Glomerulosclerosis (FSGS)

Trial Timeline

Oct 15, 2018 → Feb 14, 2023

NCT ID
NCT03448692

About PF-06730512

PF-06730512 is a phase 2 stage product being developed by Pfizer for Focal Segmental Glomerulosclerosis (FSGS). The current trial status is terminated. This product is registered under clinical trial identifier NCT03448692. Target conditions include Focal Segmental Glomerulosclerosis (FSGS).

What happened to similar drugs?

4 of 10 similar drugs in Focal Segmental Glomerulosclerosis (FSGS) were approved

Approved (4) Terminated (1) Active (6)
✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
✅DapagliflozinAstraZenecaApproved
✅Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
✅Levetiracetam + Carbamazepine + LamotrigineUCBApproved
🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
🔄Gadoxetic Acid Disodium (Primovist, BAY86-4873)BayerPhase 3
🔄XEN1101 + PlaceboXenon PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03448692Phase 2Terminated

Competing Products

20 competing products in Focal Segmental Glomerulosclerosis (FSGS)

See all competitors
ProductCompanyStageHype Score
OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved
35
DapagliflozinAstraZenecaApproved
43
Enfuvirtide + Tenofovir-EmtricitabineRochePhase 2
35
CCX140-BAmgenPhase 2
27
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamidePfizerApproved
43
VX-147Vertex PharmaceuticalsPhase 2
35
VX-147Vertex PharmaceuticalsPhase 1
29
IXPVertex PharmaceuticalsPhase 1
29
fresolimumab + fresolimumab + PlaceboSanofiPhase 2
35
GC1008 + GC1008 + GC1008 + GC1008SanofiPhase 1
29
frexalimab + brivekimig + rilzabrutinib + placeboSanofiPhase 2
42
VivaglobinCSLPhase 2
35
UCB0942UCBPhase 2
27
Levetiracetam + Carbamazepine + LamotrigineUCBApproved
43
Brivaracetam + BrivaracetamUCBPhase 2
35
LacosamideUCBPhase 2
27
UCB0942 + UCB0942 + PlaceboUCBPhase 2
35
LacosamideUCBPre-clinical
26
ARGX-117ArgenxPhase 2
36
Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
44